Westfield Capital Management Co. LP Buys 49,727 Shares of Repligen Co. (NASDAQ:RGEN)

Westfield Capital Management Co. LP grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 294,222 shares of the biotechnology company's stock after purchasing an additional 49,727 shares during the period. Westfield Capital Management Co. LP owned approximately 0.53% of Repligen worth $52,901,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Artisan Partners Limited Partnership increased its stake in shares of Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock valued at $247,558,000 after purchasing an additional 157,807 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Repligen by 2.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock valued at $222,075,000 after purchasing an additional 29,215 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 0.4% in the 4th quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company's stock valued at $127,611,000 after purchasing an additional 2,590 shares during the last quarter. Parnassus Investments LLC bought a new position in shares of Repligen in the 3rd quarter valued at $87,475,000. Finally, Northern Trust Corp increased its stake in shares of Repligen by 2.4% in the 3rd quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company's stock valued at $75,040,000 after purchasing an additional 11,204 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Buying and Selling at Repligen

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company's stock, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Karen A. Dawes sold 1,000 shares of the firm's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now directly owns 87,367 shares of the company's stock, valued at $16,892,409.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the firm's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company's stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,296 shares of company stock valued at $7,550,643. Company insiders own 1.20% of the company's stock.

Repligen Stock Down 0.4 %

RGEN traded down $0.62 during midday trading on Friday, reaching $158.16. 362,382 shares of the company were exchanged, compared to its average volume of 483,536. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The company's fifty day moving average price is $172.77 and its 200 day moving average price is $177.14. The company has a market cap of $8.84 billion, a price-to-earnings ratio of 632.67, a price-to-earnings-growth ratio of 5.30 and a beta of 1.03. Repligen Co. has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to analysts' expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business's revenue was down 17.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 earnings per share. As a group, analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RGEN. Stifel Nicolaus lifted their price target on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research note on Thursday, February 22nd. JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a report on Thursday, May 2nd. Finally, KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $197.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.